Shares of TG Therapeutics Inc (NASDAQ:TGTX) have received an average recommendation of “Buy” from the twelve analysts that are presently covering the stock. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $24.71.
A number of research analysts have recently commented on TGTX shares. Zacks Investment Research cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, March 9th. SunTrust Banks, Inc. set a $28.00 target price on shares of TG Therapeutics and gave the stock a “buy” rating in a report on Monday, March 13th. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of TG Therapeutics in a report on Tuesday, March 7th. FBR & Co reiterated an “outperform” rating and set a $26.00 target price (up from $24.00) on shares of TG Therapeutics in a report on Monday, March 6th. Finally, Ladenburg Thalmann Financial Services set a $30.00 target price on shares of TG Therapeutics and gave the stock a “buy” rating in a report on Wednesday, March 8th.
TRADEMARK VIOLATION NOTICE: “Brokerages Set TG Therapeutics Inc (TGTX) Target Price at $25.04” was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/tg-therapeutics-inc-tgtx-receives-consensus-rating-of-buy-from-brokerages-updated/652052.html.
TG Therapeutics (NASDAQ:TGTX) opened at 11.95 on Monday. The firm’s market cap is $736.79 million. TG Therapeutics has a 12-month low of $4.10 and a 12-month high of $15.05. The company has a 50-day moving average of $10.85 and a 200 day moving average of $7.63.
TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.10. The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 83.18% and a negative net margin of 47,494.08%. Equities analysts expect that TG Therapeutics will post ($1.83) EPS for the current fiscal year.
In related news, Director Laurence N. Charney sold 7,000 shares of the stock in a transaction that occurred on Tuesday, April 4th. The shares were sold at an average price of $11.17, for a total value of $78,190.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director William James Kennedy sold 8,548 shares of the stock in a transaction that occurred on Tuesday, April 11th. The stock was sold at an average price of $10.27, for a total transaction of $87,787.96. The disclosure for this sale can be found here. Company insiders own 19.00% of the company’s stock.
A number of institutional investors have recently modified their holdings of TGTX. Legal & General Group Plc increased its position in shares of TG Therapeutics by 4.1% in the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 384 shares during the period. BB&T Securities LLC acquired a new position in shares of TG Therapeutics during the first quarter valued at $121,000. Ellington Management Group LLC acquired a new position in shares of TG Therapeutics during the fourth quarter valued at $137,000. Raymond James Financial Services Advisors Inc. acquired a new position in shares of TG Therapeutics during the fourth quarter valued at $143,000. Finally, Thompson Davis & CO. Inc. acquired a new position in shares of TG Therapeutics during the first quarter valued at $154,000. Institutional investors own 50.08% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc and related companies with our FREE daily email newsletter.